Diabetes mellitus needs unrestricted evaluation of patient data to yield treatment progress. The DUTY Register;Erhebung und Verbesserung der Behandlungssituation von Patienten mit Diabetes mellitus: Das DUTY-Register

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 47, Issue 6, 2004, Pages 540-546

  Krone, W ^a   Bohm M ^c   Wohrmann A P A ^b   Bestehorn, K ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MSD Sharp and Dohme GmbH   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Cardiovascular risk factors; Diabetes mellitus; DUTY Registry; Guideline conform therapy

Indexed keywords

ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; GERMANY; HEALTH CARE QUALITY; HEALTH SERVICES RESEARCH; HUMAN; INCIDENCE; INFORMATION PROCESSING; MALE; MORTALITY; MULTICENTER STUDY; PRACTICE GUIDELINE; PUBLIC HEALTH; REGISTER; RISK MANAGEMENT; STATISTICS;

CAUSE OF DEATH; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DATA COLLECTION; DIABETES MELLITUS; FEMALE; GERMANY; GUIDELINE ADHERENCE; HEALTH SERVICES RESEARCH; HUMANS; INCIDENCE; MALE; NATIONAL HEALTH PROGRAMS; QUALITY ASSURANCE, HEALTH CARE; REGISTRIES; RISK MANAGEMENT;

EID: 4444315718     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-004-0843-2     Document Type: Article

References (20)

1. Janka HU et al. (2000) Epidemiologie und Verlauf des Diabetes mellitus in Deutschland. In: Scherbaum WA, Lauterbach KW, Renner R (Hrsg) Evidenzbasierte Diabetes-Leitlinien DDG. DDG, Düsseldorf
2. Weiderpass E et al.(2001) Cause-specific mortality in a cohort of patients with diabetes mellitus: a population-based study in Sweden. J Clin Epidemiol 54:802-809
3. Gaede P et al.(2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. NEJM 348:5383-5393
4. Liebl A et al.(2002) Kosten für Spätkomplikationen bei Diabetes mellitus Typ 2 in Deutschland. Ergebnisse der CODE-2-Studie. Med Klinik 97:713-719
5. Gozzoli V et al.(2000) Erhöhter klinischer Effekt und wirtschaftlicher Nutzen durch PROSIT. DMW 125:1154-1159
6. Assmann G et al. (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 105:310-315
7. Haffner SM et al.(1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEJM 339:229-234
8. Scherbaum WA, Landgraf R (2002) Praxis-Leitlinien der deutschen Diabetes-Gesellschaft (DDG). Diabetes Stoffwechsel 11 [Suppl 2]
9. Gray A et al. (2000) Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ 320:1373-1378
10. Monnier L (1999) The role of blood glucose-owering drugs in the light of the UKPDS, United Kinkdom Prospective Diabetes Study. Diabetes Obes Metab 1 [Suppl 2]:S14-S23
11. National Cholesterol Education Program (NCEP) Expert Panel (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 19: 2486-2497
12. Janka HU et al.(2002) Hypertonie beim Diabetes mellitus. In: Scherbaum WA, Landgraf R (Hrsg) Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft (DDG). DDG, Düsseldorf
13. Gaede P et al.(1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353:617-622
14. Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016
15. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macro-vascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713
16. Piehlmeier W et al.(1999) Screening of diabetic patients for microalbuminuria in primary care - The PROSIT-Project. Exp Clin Endocrinol Diabetes 107:244-251
17. Staessen JA et al. (2003) Cadiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 21:1055-1076
18. Blood Pressure Lowering Treatment Trialists' Collaboration (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362:1527-1535
19. Hansson L et al.(1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity andmortality in hypertension: the Capto-pril Prevention Project (CAPP) randomised trial. Lancet 353:611-616
20. Brenner BM et al.(2001) Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. NEJM 345:861-869